We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
- Authors
Hensley, M L; Schuchter, L M; Lindley, C; Meropol, N J; Cohen, G I; Broder, G; Gradishar, W J; Green, D M; Langdon, R J, Jr; Mitchell, R B; Negrin, R; Szatrowski, T P; Thigpen, J T; Von Hoff, D; Wasserman, T H; Winer, E P; Pfister, D G
- Abstract
Because toxicities associated with chemotherapy and radiotherapy can adversely affect short- and long-term patient quality of life, can limit the dose and duration of treatment, and may be life-threatening, specific agents designed to ameliorate or eliminate certain chemotherapy and radiotherapy toxicities have been developed. Variability in interpretation of the available data pertaining to the efficacy of the three United States Food and Drug Administration-approved agents that have potential chemotherapy- and radiotherapy-protectant activity-dexrazoxane, mesna, and amifostine-and questions about the role of these protectant agents in cancer care led to concern about the appropriate use of these agents. The American Society of Clinical Oncology sought to establish evidence-based, clinical practice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled on clinical treatment trials.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Vol 17, Issue 10, p3333
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1999.17.10.3333